Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 9Genitourinary 6Gastrointestinal 6Thoracic 4Breast 4Tumor-Agnostic 2Sarcoma 2Other solid neoplasm 2

Conditions

Breast Neoplasms 4Ovarian Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Leiomyosarcoma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Carcinoma, Ovarian Epithelial 1

Interventions

Trastuzumab 349Paclitaxel 310Cyclophosphamide 286Docetaxel 267Carboplatin 215Capecitabine 215Letrozole 185Fulvestrant 178Doxorubicin 166Bevacizumab 136Anastrozole 120Tamoxifen 117pertuzumab 114pembrolizumab 113Epirubicin 110exemestane 107Vinorelbine 106Gemcitabine 106Albumin-Bound Paclitaxel 92Lapatinib 84130-nm albumin-bound paclitaxel 83Radiotherapy 79palbociclib 75eribulin 73Cisplatin 69pyrotinib 66Taxes 65Everolimus 55Goserelin 50Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × rucaparib × Breast × Clear all
NCT01074970 2024-09-19

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Hoosier Cancer Research Network

Phase 2 Completed
135 enrolled 14 charts
Breast

Breast Neoplasms

NCT04171700 2023-10-02

LODESTAR

pharmaand GmbH

Phase 2 Terminated
83 enrolled 16 charts
BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinosarcoma, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Leiomyosarcoma, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT02505048 2021-06-08

RUBY

UNICANCER

Phase 2 Completed
41 enrolled
Breast

Breast Neoplasms

NCT00664781 2016-05-24

Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer

Cancer Research UK

Phase 2 Completed
78 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡